Skip to main content
. 2008 Feb 19;105(8):3005–3010. doi: 10.1073/pnas.0712237105

Fig. 5.

Fig. 5.

CTLA-4 antibody blockade accomplishes the durable regression of advanced ovarian carcinoma in the absence of significant toxicity. (A) CA-125 levels as a function of therapy. Small upward arrows indicate GVAX; downward arrows denote Ipilumimab infusions. (B) Arrow indicates a large hepatic metastasis that underwent marked regression. (C) MDX-010 augmented IgG antibodies to NY-ESO-1.